调节性B细胞和效应性B细胞：改善移植结局的生物标志物和治疗靶点的新途径？
Regulatory and Effector B Cells: A New Path Toward Biomarkers and Therapeutic Targets to Improve Transplant Outcomes?
作者信息
Cherukuri Aravind, Ding Qing, Sharma Akhil, Mohib Kanishka, Rothstein David M
机构信息
Section of Nephrology, Department of Medicine, University of Pittsburgh, Thomas E. Starzl Transplantation Institute, University of Pittsburgh School of Medicine, 200 Lothrop Street, W1545 Biomedical Science Tower, Pittsburgh, PA 15261, USA.
Department of Surgery, University of Pittsburgh, Thomas E. Starzl Transplantation Institute, University of Pittsburgh School of Medicine, 200 Lothrop Street, W1545 Biomedical Science Tower, Pittsburgh, PA 15261, USA.
出版信息
Clin Lab Med. 2019 Mar;39(1):15-29. doi: 10.1016/j.cll.2018.10.011. Epub 2018 Dec 18.
Abstract
B cells shape the alloimmune response through polarized subsets. These cells inhibit or promote immune responses by expressing suppressive or proinflammatory cytokines. Their summed activity dictates the influence of B cells on the alloimmune response. We review the evidence for regulatory B cells and effector B cells in mice and humans, discuss current limitations in their phenotypic identification, and discuss regulatory B cells as a signature for clinical renal allograft tolerance and predictive markers for allograft outcomes. We discuss the effects of therapeutic agents on regulatory B cells and potential approaches to augment their numbers as a therapeutic tool.
摘要
B细胞通过极化亚群塑造同种免疫反应。这些细胞通过表达抑制性或促炎细胞因子来抑制或促进免疫反应。它们的总体活性决定了B细胞对同种免疫反应的影响。我们综述了小鼠和人类中调节性B细胞和效应B细胞的证据，讨论了它们在表型鉴定方面目前存在的局限性，并讨论了调节性B细胞作为临床肾移植耐受性的标志以及移植结果的预测标志物。我们还讨论了治疗药物对调节性B细胞的影响以及增加其数量作为一种治疗工具的潜在方法。
相似文献
1
Regulatory and Effector B Cells: A New Path Toward Biomarkers and Therapeutic Targets to Improve Transplant Outcomes?调节性B细胞和效应性B细胞：改善移植结局的生物标志物和治疗靶点的新途径？
Clin Lab Med. 2019 Mar;39(1):15-29. doi: 10.1016/j.cll.2018.10.011. Epub 2018 Dec 18.
2
Reduced human transitional B cell T1/T2 ratio is associated with subsequent deterioration in renal allograft function.人类过渡性 B 细胞 T1/T2 比值降低与肾移植功能随后的恶化有关。
Kidney Int. 2017 Jan;91(1):183-195. doi: 10.1016/j.kint.2016.08.028. Epub 2016 Oct 28.
3
B cell subsets are modulated during allergic airway inflammation but are not required for the development of respiratory tolerance in a murine model.B 细胞亚群在变应性气道炎症期间被调节，但在小鼠模型中，它们不是呼吸耐受发展所必需的。
Eur J Immunol. 2017 Mar;47(3):552-562. doi: 10.1002/eji.201646518. Epub 2017 Jan 17.
4
IL-10-producing B cells are characterized by a specific methylation signature.产生白细胞介素-10 的 B 细胞具有特定的甲基化特征。
Eur J Immunol. 2019 Aug;49(8):1213-1225. doi: 10.1002/eji.201848025. Epub 2019 May 7.
5
Regulatory B cells and transplantation: almost prime time?调节性B细胞与移植：时机已近成熟？
Curr Opin Organ Transplant. 2018 Oct;23(5):524-532. doi: 10.1097/MOT.0000000000000559.
6
TIM-4 Identifies IFN-γ-Expressing Proinflammatory B Effector 1 Cells That Promote Tumor and Allograft Rejection.TIM-4可识别表达IFN-γ的促炎B效应细胞1，这些细胞可促进肿瘤和同种异体移植排斥反应。
J Immunol. 2017 Oct 1;199(7):2585-2595. doi: 10.4049/jimmunol.1602107. Epub 2017 Aug 28.
7
Transplantation tolerance: don't forget about the B cells.移植耐受：别忘了B细胞。
Clin Exp Immunol. 2017 Aug;189(2):171-180. doi: 10.1111/cei.12927. Epub 2017 Feb 28.
8
Regulatory and effector B cells: Friends or foes?调节性 B 细胞和效应性 B 细胞：是敌是友？
J Dermatol Sci. 2019 Jan;93(1):2-7. doi: 10.1016/j.jdermsci.2018.11.008. Epub 2018 Nov 23.
9
Interleukin-10 production and T cell-suppressive capacity in B cell subsets from atherosclerotic apoE mice.动脉粥样硬化 apoE-/- 小鼠 B 细胞亚群中的白细胞介素-10 产生和 T 细胞抑制能力。
Immunol Res. 2017 Oct;65(5):995-1008. doi: 10.1007/s12026-017-8939-6.
10
Regulatory and transitional B cells: potential biomarkers and therapeutic targets in organ transplantation.调节性和过渡性 B 细胞：器官移植中的潜在生物标志物和治疗靶点。
Curr Opin Organ Transplant. 2022 Oct 1;27(5):385-391. doi: 10.1097/MOT.0000000000001010. Epub 2022 Aug 9.
引用本文的文献
1
Oral microbiota-host interaction: the chief culprit of alveolar bone resorption.口腔微生物群-宿主相互作用：牙槽骨吸收的罪魁祸首。
Front Immunol. 2024 Feb 22;15:1254516. doi: 10.3389/fimmu.2024.1254516. eCollection 2024.
2
Unique 40-year survival after heart transplantation with normal graft function and spontaneous operational tolerance.心脏移植后 40 年独特的存活期，移植物功能正常且自发产生免疫耐受。
Clin Res Cardiol. 2024 May;113(5):661-671. doi: 10.1007/s00392-023-02341-x. Epub 2023 Nov 20.
3
TIM-4 Identifies Effector B Cells Expressing a RORγt-Driven Proinflammatory Cytokine Module That Promotes Immune Responsiveness.TIM-4识别表达由RORγt驱动的促炎细胞因子模块的效应B细胞，该模块可促进免疫反应。
bioRxiv. 2024 Oct 3:2023.09.22.558524. doi: 10.1101/2023.09.22.558524.
4
Early Cytomegalovirus Reactivation in Renal Recipients Is Associated with High Levels of B Cell Maturation Antigen Transcript Expression Prior to Transplantation.移植前，肾脏受者的巨细胞病毒早期再激活与 B 细胞成熟抗原转录本表达水平升高有关。
Int J Mol Sci. 2023 Jun 22;24(13):10491. doi: 10.3390/ijms241310491.
5
Transitional B cell cytokines risk stratify early borderline rejection after renal transplantation.移植后早期边缘性排斥反应的过渡性 B 细胞细胞因子风险分层。
Kidney Int. 2023 Apr;103(4):749-761. doi: 10.1016/j.kint.2022.10.026. Epub 2022 Nov 25.
6
Maintaining homeostatic control of periodontal bone tissue.维持牙周骨组织的内稳态控制。
Periodontol 2000. 2021 Jun;86(1):157-187. doi: 10.1111/prd.12368. Epub 2021 Mar 10.
7
Role of B cells and the aging brain in stroke recovery and treatment.B 细胞与衰老大脑在中风康复和治疗中的作用。
Geroscience. 2020 Oct;42(5):1199-1216. doi: 10.1007/s11357-020-00242-9. Epub 2020 Aug 7.
本文引用的文献
1
Belimumab in kidney transplantation: an experimental medicine, randomised, placebo-controlled phase 2 trial.贝利尤单抗治疗肾移植：一项实验医学、随机、安慰剂对照的 2 期临床试验。
Lancet. 2018 Jun 30;391(10140):2619-2630. doi: 10.1016/S0140-6736(18)30984-X. Epub 2018 Jun 14.
2
Expression of Tumor Necrosis Factor Receptor 2 Characterizes TLR9-Driven Formation of Interleukin-10-Producing B Cells.肿瘤坏死因子受体2的表达表征了Toll样受体9驱动的产生白细胞介素-10的B细胞的形成。
Front Immunol. 2018 Jan 19;8:1951. doi: 10.3389/fimmu.2017.01951. eCollection 2017.
3
TIM-4 Identifies IFN-γ-Expressing Proinflammatory B Effector 1 Cells That Promote Tumor and Allograft Rejection.TIM-4可识别表达IFN-γ的促炎B效应细胞1，这些细胞可促进肿瘤和同种异体移植排斥反应。
J Immunol. 2017 Oct 1;199(7):2585-2595. doi: 10.4049/jimmunol.1602107. Epub 2017 Aug 28.
4
Regulatory B cells in rheumatoid arthritis: Alterations in patients receiving anti-TNF therapy.类风湿关节炎中的调节性B细胞：接受抗TNF治疗患者的变化
Clin Immunol. 2017 Nov;184:63-69. doi: 10.1016/j.clim.2017.05.012. Epub 2017 May 12.
5
Human regulatory B cells in health and disease: therapeutic potential.健康与疾病状态下的人类调节性B细胞：治疗潜力
J Clin Invest. 2017 Mar 1;127(3):772-779. doi: 10.1172/JCI85113.
6
TIM-1 defines a human regulatory B cell population that is altered in frequency and function in systemic sclerosis patients.TIM-1定义了一类人类调节性B细胞群体，其在系统性硬化症患者中的频率和功能发生了改变。
Arthritis Res Ther. 2017 Jan 19;19(1):8. doi: 10.1186/s13075-016-1213-9.
7
Reduced human transitional B cell T1/T2 ratio is associated with subsequent deterioration in renal allograft function.人类过渡性 B 细胞 T1/T2 比值降低与肾移植功能随后的恶化有关。
Kidney Int. 2017 Jan;91(1):183-195. doi: 10.1016/j.kint.2016.08.028. Epub 2016 Oct 28.
8
Prospective Analyses of Circulating B Cell Subsets in ABO-Compatible and ABO-Incompatible Kidney Transplant Recipients.ABO血型相合与不相合肾移植受者循环B细胞亚群的前瞻性分析
Am J Transplant. 2017 Feb;17(2):542-550. doi: 10.1111/ajt.14013. Epub 2016 Sep 23.
9
Increased CD40 Ligation and Reduced BCR Signalling Leads to Higher IL-10 Production in B Cells From Tolerant Kidney Transplant Patients.CD40 连接增加和 B 细胞受体信号传导减少导致肾移植耐受患者 B 细胞中白细胞介素-10 产生增加。
Transplantation. 2017 Mar;101(3):541-547. doi: 10.1097/TP.0000000000001341.
10
Signatures of Tolerance or Immunosuppression?耐受还是免疫抑制的特征？
Am J Transplant. 2016 Dec;16(12):3320-3321. doi: 10.1111/ajt.13993. Epub 2016 Aug 24.
Zotero 插件